Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan hydrochloride liposome + carboplatin + serplulimab
- Development stage
- Unknown
- Lead developer
- CSPC Ouyi Pharmaceutical
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a **combination regimen** of three drugs: **irinotecan hydrochloride liposome**, **carboplatin**, and **serplulimab**. - Irinotecan hydrochloride liposome is a liposomal formulation of the topoisomerase I inhibitor irinotecan, designed to improve pharmacokinetics and tumor distribution while reducing systemic toxicity compared to free irinotecan. - Carboplatin is a platinum-based chemotherapy acting primarily via DNA cross-linking, leading to apoptosis in rapidly dividing cells. - Serplulimab is a fully human anti-PD-1 monoclonal antibody (immune checkpoint inhibitor), which blocks the programmed cell death-1 (PD-1) pathway, enhancing antitumor immune responses. This combination is being investigated as a first-line regimen for **extensive-stage small-cell lung cancer (ES-SCLC)** to potentially improve efficacy, safety, and overall survival compared to existing standard therapies. The replacement of standard irinotecan with liposomal irinotecan may further optimize safety and efficacy[3].
- Other names
- liposomal irinotecan + carboplatin + serplulimabIrinotecan Hydrochloride Liposome Injection + Carboplatin + Serplulimab
02
Targets
TOP1 (DNA Topoisomerase I)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on irinotecan hydrochloride liposome + carboplatin + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan hydrochloride liposome + carboplatin + serplulimab.